Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5949
    -0.0001 (-0.01%)
     
  • NZD/EUR

    0.5550
    +0.0010 (+0.18%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.75
    +0.18 (+0.22%)
     
  • GOLD

    2,352.60
    +10.10 (+0.43%)
     
  • NASDAQ

    17,738.20
    +307.69 (+1.77%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,293.62
    +207.82 (+0.55%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.7880
    +1.2920 (+1.40%)
     

Teva Announces Launch of Generic Version of Uceris in US

Teva Announces Launch of Generic Version of Uceris in US

On July 9, Teva announced the launch of its generic Uceris (budesonide) extended-release tablets (nine milligrams) in the United States. In November 2017, Teva prevailed in its litigation challenging Valeant Pharmaceuticals’ (VRX) Uceris patent, which was acquired through the acquisition of Salix in 2015. Teva was the first applicant to file an ANDA (abbreviated new drug application) for generic Uceris.